Dailypharm Live Search Close

Reimb extensions for Keytruda to be rediscussed later

By Lee, Tak-Sun | translator Kim, Jung-Ju

23.10.11 18:35:48

가나다라 0
Will analyze the impact of the financial sharing plan for indications with proven necessity

Reimbursement standards for Kyowa Kirin's 'Portelligio', Poteligeo Inj.’ and Pfizer Korea’s ‘Mylotarg Inj.’ have been established



MSD Korea's immunotherapy drug 'Keytruda (pembrolizumab)', which applied for a large-scale reimbursement extension, was unable to pass the first hurdle and was determined in need of rediscussions.

The authorities plan to first receive the pharmaceutical company's financial sharing plan and then decide whether to set a reimbursement standard.

The Health Insurance Review and Assessment Service announced that it decided to rediscuss the agenda of expanding the reimbursement standard for Keytruda at the 7th 2023 Cancer Disease Deliberation Committee meeting that was held on the 11th.

The indications for Keytruda that were deliberated for reimbursement extensions were ▲

Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)